Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.

被引：0
|
作者：
Milowsky, Matthew I.
O'Donnell, Peter H.
Hoimes, Christopher J.
Petrylak, Daniel P.
Flaig, Thomas W.
Moon, Helen H.
Friedlander, Terence W.
Mar, Nataliya
McKay, Rana R.
Srinivas, Sandy
Gravis, Gwenaelle
Ramamurthy, Chethan
Bupathi, Manojkumar
Bracarda, Sergio
Wright, Phoebe
Carret, Anne-Sophie
Yu, Yao
Matsuda, Tara
Kataria, Ritesh S.
Rosenberg, Jonathan E.
机构：
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Duke Univ, Duke Canc Inst, Durham, NC USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[6] Kaiser Permanente Southern Calif Reg, Hematol Oncol, Riverside, CA USA
[7] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA
[8] Univ Calif Irvine, Orange, CA 92668 USA
[9] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[10] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[11] Inst Paoli Calmettes, Marseille, France
[12] Univ Texas Hlth, MD Anderson Canc Ctr, San Antonio, TX USA
[13] Rocky Mt Canc Ctr, Littleton, CO USA
[14] Azienda Osped Santa Maria, Terni, Italy
[15] Seagen Inc, Bothell, WA USA
[16] Astellas Pharma Inc, Northbrook, IL USA
[17] Merck & Co Inc, Rahway, NJ USA
[18] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[19] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439
引用
收藏
页数：1
相关论文
共 31 条
  • [21] Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H
    O'Donnell, Peter H.
    Hoimes, Christopher J.
    Rosenberg, Jonathan E.
    Petrylak, Daniel P.
    Mar, Nataliya
    Barata, Pedro C.
    Srinivas, Sandy
    Gourdin, Theodore Stewart
    Henry, Elizabeth
    Bilen, Mehmet Asim
    George, Saby
    Rao, Santosh
    Assikis, Vasileios J.
    Burgess, Earle F.
    Lewis, Brian E.
    Bowman, I. Alex
    Brancato, Sam Joseph
    Mildiner-Earley, Shirly
    Zhu, Yalin
    Flaig, Thomas W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Valderrama, B. Perez
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Gauna, D. E. Castellano
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    van der Heijden, B. M. S. Homet Moreno
    ANNALS OF ONCOLOGY, 2023, 34 : S1340 - S1340
  • [23] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Perez Valderrama, B.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano Gauna, D. E.
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1557 - S1558
  • [24] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
    Rosenberg, Jonathan E.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    Penel, Nicolas
    Zagonel, Vittorina
    Sierecki, Mitchell Robert
    Bao, Weichao
    Zhou, Yinghui
    Ellinghaus, Peter
    Sweis, Randy F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy.
    Petrylak, Daniel
    Rosenberg, Jonathan
    Duran, Ignacio
    Loriot, Yohann
    Sonpavde, Guru
    Wu, Chunzhang
    Gartner, Elaina
    Melhem-Bertrandt, Amal
    Powles, Thomas
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 59 - 60
  • [26] Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108
    O'Donnell, Peter H.
    Arkenau, Hendrick Tobias
    Sridhar, Srikala S.
    Ong, Michael
    Drakaki, Alexandra
    Spira, Alexander, I
    Zhang, Jingsong
    Gordon, Michael S.
    Degboe, Arnold N.
    Gupta, Ashok K.
    Mukhopadhyay, Pralay
    Huang, Wenmei
    Abdullah, Shaad E.
    Angra, Natasha
    Roskos, Lorin K.
    Guo, Xiang
    Friedlander, Terence
    CANCER, 2020, 126 (02) : 432 - 443
  • [27] Re: Patient-Reported Outcomes and Inflammatory Biomarkers in Patients With Locally Advanced/Metastatic Urothelial Carcinoma Treated With Durvalumab in Phase 1/2 Dose-Escalation Study 1108
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1513 - 1514
  • [28] Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial
    McGregor, Bradley
    O'Donnell, Peter H.
    Balar, Arjun
    Petrylak, Daniel
    Rosenberg, Jonathan
    Yu, Evan Y.
    Quinn, David, I
    Heath, Elisabeth, I
    Campbell, Mary
    Hepp, Zsolt
    McKay, Caroline
    Steinberg, Joyce
    Regnault, Antoine
    Mazerolle, Flora
    Galsky, Matthew D.
    EUROPEAN UROLOGY, 2022, 81 (05) : 515 - 522
  • [29] Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
    Rosenberg, Jonathan E.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    Penel, Nicolas
    Zagonel, Vittorina
    Sierecki, Mitchell Robert
    Piciu, Ana-Maria
    Ellinghaus, Peter
    Sweis, Randy F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
    Han, Hyo
    Diab, Sami
    Alemany, Carlos
    Basho, Reva
    Brown-Glaberman, Ursa
    Meisel, Jane
    Pluard, Timothy
    Cortes, Javier
    Dillon, Patrick
    Ettl, Johannes
    Kuemmel, Sherko
    Sanchez, Luis Manso
    Oliveira, Mafalda
    O'Shaughnessy, Joyce
    Papish, Steven
    Sinha, Rajni
    Sterrenberg, Danielle
    Stringer-Reasor, Erica
    Tsai, Michaela
    Vazquez, Rafael Villanueva
    Wuerstlein, Rachel
    Wang, Yinghui
    Wang, Zejing
    Boni, Valentina
    CANCER RESEARCH, 2020, 80 (04)
1234